HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Download All
Get up to date on the new antimicrobial agents in the management of HABP and VABP, including MDR gram-negative infections, at this live symposium with case discussions and a faculty question and answer session. Reinforce your learning with an on-demand video, downloadable slides, a podcast, and companion expert-authored commentaries.
Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Keith S. Kaye, MD, MPH
Jason Pogue Headshot
Jason M. Pogue, PharmD

ClinicalThought

HABP and VABP are extremely challenging infections to manage for various reasons. Here’s my take on how new recommendations and tools can help lead to early effective therapy.

Keith S. Kaye, MD, MPH Released: January 24, 2022

Guidelines for hospital-acquired and ventilator-associated bacterial pneumonia are great, but you have to bring it back to the individual.

Lilian Abbo Headshot Lilian Abbo, MD, FIDSA Released: February 11, 2022

The problem with antibiograms is that they capture essentially the first specimen from a patient, and flora change with time and treatment.

Lilian Abbo Headshot Lilian Abbo, MD, FIDSA Released: March 8, 2022

Working closely with frontline ICU pharmacists and physicians is vital to obtaining microbiological histories, recent antimicrobial exposures, and drug allergies to optimize therapy on an individual level.

Jason Pogue Headshot Jason M. Pogue, PharmD Released: April 14, 2022

Downloadable Slideset

Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Lilian Abbo Headshot Lilian Abbo, MD, FIDSA Keith S. Kaye, MD, MPH Jason Pogue Headshot Jason M. Pogue, PharmD Released: February 18, 2022

Podcast

Listen to expert insights on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot Lilian Abbo, MD, FIDSA Jason Pogue Headshot Jason M. Pogue, PharmD
Released: March 15, 2022

Video Module

Hear expert insights on key concepts in HABP/VABP and Gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot Lilian Abbo, MD, FIDSA Jason Pogue Headshot Jason M. Pogue, PharmD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Pharmacists: 1.75 contact hours (0.175 CEUs) Released: March 23, 2022 Expired: March 22, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings